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Classic congenital adrenal hyperplasia aﬀects approximately 1 in 15,000 children. Current treatment strategies using multiple daily
doses of hydrocortisone lead to suboptimal outcomes. We tested the hypothesis that nocturnal administration of dexamethasone
will suppress the hypothalamic-pituitary-adrenal axis more eﬀectively than standard hydrocortisone treatment by blocking the
inherent diurnal secretion of ACTH. We performed a pilot study of ﬁve prepubertal patients comparing CAH control during two
24-hour hospitalizations, one on hydrocortisone and the other on dexamethasone. The patterns of adrenal suppression diﬀered
markedly between hydrocortisone and nocturnal dexamethasone, with signiﬁcant suppression of the morning rise in ACTH, 17-
hydroxyprogesterone, and androstenedione while on dexamethasone. On hydrocortisone therapy, there is a marked variation in
ACTH and adrenal hormones depending on time of day and timing of hydrocortisone administration. Longer-term studies are
needed to investigate the lowest eﬀective dose and potential toxicity of nocturnal dexamethasone to determine its utility as a
therapy for CAH.
1.Introduction
Congenital adrenal hyperplasia results from a defect in the
adrenal steroid biosynthetic pathway leading to hypocorti-
solemia, resultant elevated ACTH levels and hyperandro-
genism. In theory, glucocorticoid replacement should restore
normocortisolemia, thus inhibiting excess ACTH secretion
andcorrectingthehyperandrogenicstate.Inreality,however,
adequate adrenal androgen suppression is diﬃcult to achieve
as, even in the face of ACTH levels in the normal range,
adrenal steroid precursors proximal to the enzymatic defect
will still accumulate and maintain the hyperandrogenic
state [1]. Supraphysiologic doses of glucocorticoids may be
needed to suppress excess androgen production at the risk of
impairedlineargrowth[2,3].Ontheotherhand,suboptimal
adrenal androgen suppression with inadequate hydrocor-
tisone therapy may accelerate linear growth, resulting in
premature closure of the epiphyses and an impaired ﬁnal
adult height [4]. There is no consensus as to the optimal
treatment or monitoring regimen for congenital adrenal
hyperplasia.
Our study is an open-labeled pilot study comparing
the eﬃcacy of nocturnal dexamethasone versus standard
hydrocortisone therapy in the control of the hypothalamic-
pituitary-adrenal axis in prepubertal subjects with classic
salt-wasting congenital adrenal hyperplasia. We hypothesize
that the administration of a long-acting glucocorticoid,
dexamethasone, being given at night will more eﬀectively
suppress the pituitary gland diurnal secretion of ACTH,
most of which occurs during the night. There is much
debate in the literature as to the dose equivalency between
hydrocortisoneanddexamethasonewithratiosranging from
17:1 to 80:1 [5–8]. As our study was intended as an initial
proof of principle pilot study, we chose a dose equivalency of
50:1 in order to ensure our ability to detect a diﬀerence in
hormonal proﬁles on the two medication regimens, prior to
exploring the lowest eﬀective dose and potential toxicities of
dexamethasone in a subsequent, longer-term study.2 International Journal of Pediatric Endocrinology
2.MaterialsandMethods
Subjects were eligible for enrollment if they had clas-
sic salt-wasting 21-hydroxylase-deﬁcient congenital adrenal
hyperplasia with a bone age below 8 years of age and a
chronological age above two years of age. This age group was
chosen as this study was designed as a pilot study with the
intentionofeventuallyperformingfurtherstudiesexamining
long-term outcomes such as growth velocity. Therefore, we
limited enrollment to prepubertal children so as to avoid
the growth promoting eﬀects of sex steroids. Diagnosis was
conﬁrmed by reviewing the medical record. Subjects were
excluded if they required glucocorticoid therapy for another
medical indication besides CAH. Subjects were also excluded
if they were taking any medications that interfered with the
metabolism or bioavailability of glucocorticoids.
Subjects were recruited from the outpatient Endocrinol-
ogy clinic at Children’s Hospital Boston. This study was
approved by the Children’s Hospital Boston Committee on
Clinical Investigation. Informed consent was obtained from
both parents of all subjects. The trial was registered at
http://clinicaltrials.gov/, identiﬁer # NCT00621985.
There were 16 subjects who met the study inclusion
criteria. Six subjects consented to inclusion in the study.
IV access could not be obtained in one subject, and the
remaining ﬁve subjects (2 females) were included in the
study. Four completed the entire protocol while the ﬁfth
only completed the baseline admission due to intravenous
accessdiﬃculties.Subjects’agesrangedfrom2to7yearswith
bone ages between 1 year 9 months and 7 years 10 months.
Four of the subjects received hydrocortisone three times
per day and Subject 3 received it twice per day as baseline
therapy. Total daily hydrocortisone doses ranged from 6.94
to 18.52mg/m2/day. All subjects were on Fludrocortisone
for mineralocorticoid replacement with doses ranging from
0.05mg to 0.1mg (See Table 1 in supplementary material
available online at doi: 10.1155/2010/347636; it includes
detailed demographic information).
Subjects were admitted to the Clinical and Translational
Science Unit for two 24-hour inpatient hospitalizations, the
ﬁrst on standard hydrocortisone therapy and the second
on dexamethasone therapy. During each admission, subjects
were admitted to the hospital at noon on day 1. They had
a drawing IV placed, and the study commenced with the
ﬁrst blood draw at 15:00. Thirteen blood samples were
drawn over a 23-hour period for the measurement of ACTH,
17-hydroxyprogesterone and, androstenedione. A fasting
08:00 blood draw was performed for serum glucose and
insulin levels. Additionally, 24-hour urine collections were
performed for the measurement of creatinine, pregnanetriol,
and17-ketosteroidsinthosesubjectswhoweretoilettrained.
All samples except for ACTH were handled as per
standard operating protocols of the Children’s Hospital
Boston clinical laboratory. ACTH samples were collected in
EDTA tubes on ice. They were immediately spun down in
a refrigerated centrifuge for 10 minutes and then aliquoted
into 1mL aliquots. They were then frozen at −20
◦C until
the completion of each admission, at which point they
were transferred to the clinical laboratories for further
processing. 17-hydroxyprogesterone and androstenedione
were quantiﬁed by liquid chromatography tandem mass
spectrometry (LC-MS/MS) with a C18 LC column. Prior to
injection, the analyte was isolated from the serum/plasma by
liquid-liquid extraction. An internal standard was included
in each sample to account for sample loss throughout
the sample preparation procedure. The assay was linear
between 10 and 1000ng·dL
−1. The intra-assay CV, for
three levels of QC, determined over three months of
instrumentoperationwere15.9%and14.3%for17OHPand
androstenedione respectively. An IMMULITE 2000 analyzer
(Siemens Medical Solutions Diagnostics, Los Angeles, CA,
USA) was employed for ACTH quantiﬁcation. The solid-
phase, two-site sequential chemiluminescent immunometric
assay has an analytical sensitivity of 5pg·mL
−1 and provides
a linear response between 5 and 1250pg·mL
−1. The intra-
assayCVs,forthreeQClevels,determinedoverthreemonths
of instrument operation averaged out at 4.1%. Cortisol was
measured via an electrochemiluminescence immunoassay
on the cobas e601 automated analyzer (Roche Diagnostics,
Indianapolis,IN,USA).Thelowerlimitofdetectionandthat
of quantiﬁcation for cortisol are ≤0.036 and 0.31μg·dL
−1,
respectively. The assay is linear over a concentration range of
0.036–63.4μg·dL
−1.Theintra-assayCVs,forthreeQClevels,
determined over three months of instrument operation
averaged out at 2.3%. 17-Ketosteroids were quantiﬁed in
urine using a Beckman DU-800 spectrophotometer. The
assay has a linear range from 1 to 40mg·L
−1. The interassay
CV for analyte levels of 5 and 23mg·L
−1 were 14 and 8%,
respectively. Aliquots of urine were mixed with an internal
standard and incubated overnight with glucuronidase to
free the pregnanetriol from glucuronide conjugates. The
pregnanetriol was then extracted, reduced, and subjected to
aluminaopencolumnchromatography.Thesilanederivative
of the collected pregnanetriol peak was analyzed using GC
withaﬂameionizationdetector.Astandard,ablank,andtwo
control pools are included in each assay batch. The assay was
linear between 0.05 and 20mg·dL
−1. The inter- and intraday
assay CVs, respectively, averaged out at 8.1 and 15.5% for the
two control levels tested.
Standard therapy was deﬁned as the individual subject’s
baseline hydrocortisone and ﬂudrocortisone regimen as
determined by their primary endocrinologist. Hydrocorti-
sone doses were given at 08:00, 15:00, and 22:00 for subjects
on a three-dose regimen and at 08:00 and 22:00 for the
subject on a two-dose regimen. Dexamethasone was given at
a reduction dose of 1:50 of the total daily hydrocortisone
dose of each patient. The dexamethasone dose was given at
22:00 for three days starting on the evening 2 days prior to
the second admission. The subject was then admitted on the
afternoon of the third day for the second 24-hour admission.
The second admissions occurred between 2 and 8 weeks after
theﬁrstadmission.Alllabsampleswereobtainedpriortothe
administration of a medication dose at the same time point.
On each admission, parents were questioned regarding
how well the patient slept over the prior three days. A
ﬁve-point Likert scale was used ranging from 1 = Very Poorly
to 5 = Very Well. As a measure of self-reported compliance,
parents were also asked to report the number of doses ofInternational Journal of Pediatric Endocrinology 3
hydrocortisone missed in the past 3 days and number of
doses of hydrocortisone missed on average per week over the
preceding 3 months. All subjects were reported to be in good
compliance.
Area under the curves for the 23-hour proﬁles of 17-
hydroxyprogesterone, androstenedione, and ACTH were
calculated by the trapezoidal rule. Values less than the assay
limit were estimated as half the diﬀerence between the
lower assay limit and zero. AUCs were log transformed for
analysis to reduce skew. Two-sided paired t-tests were used
to compare mean log-transformed AUC, mean fasting blood
glucose, and insulin values on the two therapeutic regimens.
3. Results
Figures 1–5 depict the 24-hour hormonal proﬁles for each of
the subjects. Normal values in this age range for ACTH, 17-
hydroxyprogesterone, and androstenedione are 6–55pg/ml
(1.3–12.2pmol/L), less than 100ng/dl (3025pmol/L), and
10–47ng/dl (349–1641pmol/L), respectively. In all subjects
on standard therapy, ACTH, 17-hydroxyprogesterone, and
androstenedione values were suppressed throughout the
night and rose sharply at approximately 04:00. These
values peaked prior to the administration of the 08:00
hydrocortisone dose. They then dropped signiﬁcantly by
10:00. These values tended to rise at 12:00 as the morning
hydrocortisone dose eﬀect waned until the administration of
another dose of hydrocortisone at 15:00. In the subject on
twice daily hydrocortisone therapy, these values continued
to rise until 18:00. Subjects 2, 3, and 5 demonstrate a fall in
hormonalvaluesbetween18:00and20:00withoutadditional
hydrocortisone administration. This indicates the presence
of an intact diurnal rhythm in these subjects despite lack of
negative feedback from cortisol. All subjects’ ACTH, 17OHP,
and androstenedione levels were suppressed after the 20:00
dose of hydrocortisone and remained low throughout the
night.Therewasexquisiteconcordanceinthe24-hourcurves
for all 3 hormones.
In all subjects, nocturnal dexamethasone administra-
tion led to blunting of the early morning rise in ACTH,
17OHP, and androstenedione. This eﬀect lasted throughout
the day with a trend for higher hormonal levels in the
afternoon as the dexamethasone eﬀect waned. The degree
of suppression of the hypothalamic-pituitary-adrenal axis
depended on the level of suppression on standard therapy.
Figure 6 summarizes the percent diﬀerence in the integrated
area under the curves for the 23-hour hormonal proﬁles
as well as the urine 17-ketosteroids. Mean log AUC was
signiﬁcantly lower for ACTH (P = .031) and marginally
signiﬁcantly lower for 17OHP (P = .098) on dexamethasone
therapy. There was no statistical diﬀerence between mean
log Androstenedione (P = .475) or 17-ketosteroids (P =
.175) on the two regimens. Urine samples were only available
for 3 subjects (Supplementaral Figures 1 and 2). Mean
urine pregnanetriol levels were 2.4 and 0.1mg/24 hours
on standard and dexamethasone therapy, respectively. Mean
urine 17-ketosteroids levels were 2.6 and 1.4mg/24 hours on
standard and dexamethasone therapy, respectively.
The mean fasting blood sugar was 83mg/dl on both
standard and dexamethasone therapy (P = 1). Mean fasting
insulin levels were 6.95 and 9.63mcIU/ml on standard and
dexamethasone therapy, respectively (P = .40). Mean sleep
scores were 4 and 4.5 on standard and dexamethasone ther-
apy respectively, indicating that nocturnal dexamethasone
did not lead to sleep disruption in this short time frame.
4. Discussion
Optimal monitoring and treatment of congenital adrenal
hyperplasia remains quite diﬃcult despite the availability of
multiple glucocorticoid preparations and hormonal assays.
Traditional dogma suggests that prepubertal children should
be treated with a hydrocortisone dose divided twice or
thrice daily and the degree of control should be assessed by
monitoring 17-hydroxyprogsterone, androstenedione, and
possibly testosterone levels [9, 10]. Invariably, the greatest
apparent adrenal androgen suppression occurs 2–4 hours
after each dose [11], and the duration of this suppressive
eﬀect is limited. Also, standard treatment with two or
three daily doses of corticosteroids [12], treatment with
diﬀerent prednisone regimens [13] ,a n de v e nn o c t u r n a l
administration of the total daily dose of hydrocortisone [11]
donotpreventapronouncedrisein17-hydroxyprogesterone
level after midnight, reﬂecting lack of eﬀective suppression
of the nocturnal ACTH peak. However, when hydrocor-
tisone is administered at 03:00AM at 33% of the total
daily dose, a marked reduction in the morning serum
17-hydroxyprogesterone levels is observed [14], indicating
adequate suppression of the early morning rise in ACTH.
Additionally, a recent study examining the eﬃcacy of an
extended-release hydrocortisone demonstrated good early
morning control of ACTH and adrenal androgen production
with waning eﬀects in the afternoon [15].
We hypothesized that a single nocturnal daily dose of
dexamethasone, a longer-acting glucocorticoid [16], would
lead to an improved suppression of the HPA axis. Several
studies on dexamethasone treatment for congenital adrenal
hyperplasia have been performed; however, most were
done in adult patients at supraphysiologic hydrocortisone
equivalent doses, often resulting in cushingoid side eﬀects
[16–20]. Hayek et al. [21] administered a single nocturnal
dose of dexamethasone to four postpubertal patients with
CAH, two of whom had the classic salt-wasting type. They
demonstrated adequate suppression of adrenal androgens
by measuring urinary 17-ketosteroid and pregnanetriol. No
blood hormones were measured during this study nor was
there any measure of the diurnal variation in hormone
release. Rivkees and Crawford [7] reported their clinical
experience with treating prepubertal children with CAH
with single daily dose dexamethasone in the morning. Their
patients had predicted adult heights that were comparable
to target mid-parental heights with normal levels of adrenal
hormones. Recently, Rivkees and Stephenson [22]r e p o r t e d
on their experience in treating young children with dex-
amethasone starting in infancy. These children had normal
growth patterns. These two studies demonstrate that it is4 International Journal of Pediatric Endocrinology
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Figure 1: Subject 1 blood ACTH (squares) and 17 hydroxyprogesterone (17OHP, triangles) over 23-hour period while on hydrocortisone
(HC, black) or dexamethasone (Dex, brown). Androstenedione levels were less than assay at all time points on both regimens in this patient.
To convert to SI units, multiply ACTH by 0.2222(pmol/L), 17OHP by 30.2572(pmol/L), and Androstenedione by 34.9162(pmol/L).
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Figure 2: Subject 2 blood ACTH, 17 hydroxyprogesterone and androstenedione (circles) over 23-hour period while on hydrocortisone or
dexamethasone. Abbreviations and symbols as in Figure 1.
feasible to treat prepubertal patients with single daily dose
dexamethasone while maintaining adequate growth. These
studies did not include any comparison groups nor did
they examine our hypothesis regarding the timing of dosing
aﬀecting the eﬃcacy of ACTH suppression.
Our pilot study is unique as it is a crossover study com-
paring the eﬀectiveness of standard hydrocortisone therapy
versus nocturnal dexamethasone therapy in a group of pre-
pubertal patients with classic congenital adrenal hyperplasia.
We demonstrated that nocturnal administration of the long-
acting glucocorticoid dexamethasone given at 1/50th of the
total daily hydrocortisone dose more eﬀectively suppresses
the morning rise in ACTH and adrenal androgens. While
ACTH is not routinely used to monitor therapy in CAH,
it has been shown to correlate with other clinical markers
of control [23]. From a physiologic perspective, ACTH is
the most proximal measurable indicator of the activation
of the HPA axis and suppression by exogenous glucocor-
ticoid treatment. It is the stimulus for adrenal hormone
production and is responsible for its diurnal rhythm. Our
study clearly demonstrates coordinated changes in ACTH
and adrenal steroid blood levels throughout the day while on
hydrocortisone therapy. This indicates that the steroid levels
largely reﬂect regulation by ACTH. While we had a limited
sample size, we believe that our results prove in principle
thatnocturnaldexamethasoneadministrationcouldbemore
eﬀective than thrice daily administration of hydrocortisone
for the treatment of CAH.
Our study is limited in several respects. It was a short-
term study that only used one dose of dexamethasone in a
smallnumberofsubjects.Asmentionedabove,thereismuch
debate as to the dose equivalency between hydrocortisoneInternational Journal of Pediatric Endocrinology 5
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Figure 3: Subject 3 blood ACTH, 17 hydroxyprogesterone, and androstenedione (circles) over 23-hour period while on hydrocortisone or
dexamethasone. Abbreviations and symbols as in Figures 1 and 2.
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Figure 4: Subject 4 blood ACTH, 17 hydroxyprogesterone, and androstenedione (circles) over 23-hour period while on hydrocortisone or
dexamethasone. Abbreviations and symbols as in Figures 1 and 2.
and dexamethasone with ratios ranging from 17:1 to
80:1 [5–7, 24]. Glucocorticoids have diﬀerent potencies
depending on the physiologic eﬀect being investigated [5].
It is possible that the dexamethasone used in our study was
moreeﬀectivemerelybecauseitrepresentedahighereﬀective
dose of glucocorticoid. While this is a deﬁnite possibility,
many of our patients had multiple ACTH, 17OHP, and
androstenedione levels that were not completely suppressed
while on the dexamethasone therapy, as well as normal
24-hour urine values of 17-ketosteroids. Subjects 1 and 2,
who were given the lowest doses of dexamethasone as a
function of body surface area, had clear diurnal rhythms in
hormone release (Figures 1 and 2). These ﬁndings indicate
that their adrenal glands were not completely suppressed by
dexamethasone. Additionally, we did not ﬁnd any rise in the
fasting blood sugar or insulin levels which would be markers
of overtreatment. However, all three subjects who completed
the 24-hour urine collections did have very low values of
pregnanetriol while on dexamethasone, and subjects 3 and
4 (who were given the highest doses of dexamethasone as
a function of body surface area) had minimal variability
in ACTH throughout the day. While it does not appear
that the adrenal glands were completely suppressed, this
does likely reﬂect a degree of oversuppression. Given the
wide range of quoted potencies for dexamethasone in the
literature, we chose a dose equivalency in the middle of the
range. Ultimately, a longer-term dose-ﬁnding study must be
done in which the dose of dexamethasone will be titrated6 International Journal of Pediatric Endocrinology
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Figure 5: Subject 5 blood ACTH, 17 hydroxyprogesterone, and androstenedione (circles) over 23-hour period while on hydrocortisone.
Subject 5 did not complete the dexamethasone admission due to technical diﬃculties. Abbreviations and symbols as in Figures 1 and 2.
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based on clinical parameters while monitoring for signs of
oversuppression. Based on our study, we believe that dexam-
ethasone has a potency at least 50 times greater than that
of hydrocortisone. There are also concerns that long-term
administration of nocturnal dexamethasone could lead to
suppression of growth hormone secretion [25]. Given these
concerns, we believe that further research is necessary for
comparing the eﬃcacy of various glucocorticoid regimens,
including nocturnal dexamethasone, over a period of time
that allows assessment of HPA axis suppression and potential
sequelae of glucocorticoid overtreatment, prior to deciding
whether this approach could be a part of routine care.
Additionally, our results demonstrate some important
points for monitoring of therapy in CAH regardless of
treatment regimen. The data clearly show that there is
exquisite synchronicity in the patterns of ACTH, 17-
hydroxyprogesterone, and androstenedione production. It
has been suggested that individual androstenedione values
may be a better marker of adrenal suppression than 17-
hydroxyprogesterone [26–28] as androstenedione purport-
edlyhaslessdiurnalvariability[29].Ourdatadonotsupport
this belief as poorly controlled patients had androstenedione
values that varied up to 13 folds during a 24-hour period.
The magnitude of change is smaller than that of 17-
hydroxyprogesterone, but the degree of variation is still quite
marked. It is possible that we were able to better delineate
this variation due to our use of tandem mass spectrometry to
measure androstenedione levels.
Our study also illustrates the high variability in adrenal
hormone production depending on both the time of day
and timing of sample acquisition relative to glucocorticoid
administration. Three of our patients’ hormonal values
fell in the early evening without additional hydrocortisone
administration suggesting that patients with congenital
adrenal hyperplasia continue to have an inherent diurnal
rhythm for ACTH secretion even in the absence of negative
glucocorticoid feedback. In fact, it appears that the normal
night-time diurnal suppression of ACTH release is hierar-
chically more important than negative feedback suppression
of ACTH by cortisol as the former occurs in the absence
of the latter. Therefore, we conclude that administration of
short-acting glucocorticoids after 18:00 does not assist in
suppression of the HPA axis as it is already inherently shut
oﬀ.V e r m ae ta l .[ 15] drew a similar conclusion in their
study which is also supported by a recent study by GermanInternational Journal of Pediatric Endocrinology 7
et al. [30] that showed no diﬀerence in disease control as
assessed by 08:00 hormonal levels in subjects receiving a
higher dose of hydrocortisone in the evening versus the
morning. Furthermore, these authors showed that there was
no diﬀerence in sleep quality as measured by actigraphy
on the two regimens. Our study supports this ﬁnding by
showing that nocturnal administration of dexamethasone,
a steroid signiﬁcantly more potent that hydrocortisone, did
not lead to sleep disturbance in any of our patients.
Additionally, our study clearly demonstrates how a
single measurement of 17OHP or androstenedione can be
misleading in assessing a patient’s overall level of adrenal
suppression. Within-subject variation of 17OHP was as great
as 40 folds over a 24-hour period. This variability can lead
to both over- and underestimates of the degree of adrenal
suppression. For example, subject 3 had a 17OHP value of
560ng/dl and androstenedione of 16ng/dl at noon. His peak
values were 4140ng/dl and 67ng/dl, respectively (Figure 3).
Thus, the noon value, which represented the eﬀect of the
08:00 hydrocortisone administration, could falsely reassure
the clinician that this patient is well controlled when he is
actually undertreated. As a result of this phenomenon, some
have advocated measuring hormonal levels at 08:00 prior to
the administration of the morning glucocorticoid dose [10,
31]. However, this too can be misleading as is demonstrated
by subject 4 (Figure 4). This patient had an 08:00 17OHP
value of 655ng/dl and androstenedione of 20ng/dl, both
values within the target range for good control of CAH.
However, the remainder of the 17OHP values were all less
than 100ng/dl, and the majority of the androstenedione
values were less than 10ng/dl. This patient’s 24-hour proﬁle
suggests that she was being over treated while the 08:00 value
provided false reassurance of good control. Thus, we urge
great caution in the interpretation of any single 17OHP or
androstenedione value at any time of day. It is possible that
24hoururinecollectionsofadrenalmetabolitessuchaspreg-
nanetriol and 17-ketosteroids, although cumbersome, more
accurately reﬂect the overall degree of HPA activity as they
integrate hormonal secretion over an entire diurnal cycle.
5. Conclusions
We have performed a crossover pilot study comparing the
eﬃcacy of standard hydrocortisone therapy versus nocturnal
dexamethasone therapy in children with congenital adrenal
hyperplasia. Nocturnal dexamethasone administration led
to a decrease in the morning rise in ACTH and adrenal
hormones, which we believe may translate into improved
long term outcomes. Finally, our study clearly demon-
strates the variability in ACTH, 17-hydroxyprogesterone,
and androstenedione levels in relation to time of day and
timing of glucocorticoid administration. Further research
comparing the long-term safety and eﬃcacy of various
glucocorticoid regimens for the treatment of children with
congenital adrenal hyperplasia is needed, in the hope of
designing a better treatment of CAH that includes more
robust suppression of the adrenal axis combined with less
glucocorticoid toxicity.
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